Catalyst Pharmaceuticals to Participate in the BofA Securities CNS Therapeutics Virtual Conference 2024GlobeNewsWire • 10/01/24
Catalyst Pharmaceuticals Announces Sub-Licensee DyDo Pharma Received Approval to Commercialize FIRDAPSE® in JapanGlobeNewsWire • 09/24/24
Santhera Announces Half-Year 2024 Financial Results and Provides Corporate UpdateGlobeNewsWire • 09/12/24
Wall Street Analysts See a 56.65% Upside in Catalyst (CPRX): Can the Stock Really Move This High?Zacks Investment Research • 08/15/24
Catalyst (CPRX) Reports Q2 Earnings: What Key Metrics Have to SayZacks Investment Research • 08/08/24
Catalyst Pharmaceutical (CPRX) Beats Q2 Earnings and Revenue EstimatesZacks Investment Research • 08/08/24
Catalyst Pharmaceuticals Reports Strong Second Quarter 2024 Financial Results and Provides Corporate UpdateGlobeNewsWire • 08/07/24
Catalyst Pharmaceuticals Enters Into an Exclusive License, Supply and Commercialization Agreement with Kye Pharmaceuticals for AGAMREE® in CanadaGlobeNewsWire • 07/24/24
Catalyst Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 7, 2024GlobeNewsWire • 07/22/24
Catalyst Pharmaceuticals Receives U.S. FDA Approval For Increased Maximum Daily Dose For FIRDAPSE®GlobeNewsWire • 05/30/24
Catalyst Pharmaceuticals to Participate at the Jefferies Global Healthcare Conference 2024GlobeNewsWire • 05/28/24
Top 10% Biotech Stock Catalyst Pharma Doubles Wall Street's Profit ViewsInvestors Business Daily • 05/08/24
Catalyst Pharmaceuticals Reports Solid First Quarter 2024 Financial Results and Provides Business UpdateGlobeNewsWire • 05/08/24
Santhera Announces Preliminary Unaudited 2023 Annual Results and Provides Corporate Update Ahead of Full Report Publication in MayGlobeNewsWire • 04/25/24